Co-Diagnostics Inc. (NASDAQ: CODX) announced a 1-for-30 reverse stock split effective January 2, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and the stock will continue trading under the symbol 'CODX' on a split-adjusted basis.

Co-Diagnostics' joint venture CoSara will participate in VIROCON 2025, presenting ongoing preclinical studies for tuberculosis and HPV tests on their PCR point-of-care platform, with promising early results supporting advancement to clinical performance testing.

Co-Diagnostics will attend the Global Health Exhibition 2025 in Riyadh, showcasing their upcoming PCR point-of-care platform and exploring a potential joint venture in the Middle East and North Africa region.

Co-Diagnostics, Inc. closed a registered direct offering of 9,619,000 common stock shares at $0.40 per share, raising approximately $3.8 million for working capital and general corporate purposes.

Co-Diagnostics reported a Q2 2025 GAAP EPS loss of $0.23, slightly improving from the prior year. Revenue fell sharply to $0.2 million from $2.7 million in Q2 2024, with the company still in a pre-commercial phase focused on developing infectious disease diagnostic platforms.